Answers are grounded in this paper and cite their sources.
Gastric cancer is the second most lethal cancer world-wide, and has a poor overall 5-year survival rate of <25 % which is largely due to both late detection of this aggressive disease and the limited effectiveness of current treatment options. Surgery alone can only “cure” a small proportion of patients with locally-invasive advanced gastric cancer, and while adjuvant perioperative chemotherapy (e.g. epirubicin, cisplatin, fluorouracil) reduces tumour sizes and improve the 5-year survival rate [1], patient outcomes are largely marginal and often associated with tumour re-occurrence. Moreover, the need for early detection (i.e. screening) and treatment strategies to improve patient survival rates is highlighted by the disappointing results of phase II/III clinical trials worldwide aimed at investigating the safety and efficacy
No takes yet. Share an insight, caveat, or question.
McCormack et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: